Exagen Inc. To Announce Fourth Quarter And Full Year 2025 Financial Results On March 10, 2026

2026-02-24 09:02:19

(MENAFN- GlobeNewsWire - Nasdaq) CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT).

Conference Call & Webcast:

U.S. dial-in: 877-407-0890
International dial-in: +1 201-389-0918
Webcast: Available via the Exagen investor relations website at exagen

Replay: A telephone replay will be available until Tuesday, March 24, 2026:

U.S. replay: 877-660-6853
International replay: +1 201-612-7415
Replay passcode: 13757484
Webcast: A recording of the webcast will be available one hour after the call concludes via the Exagen investor relations website at

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen's mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company's flagship product, AVISE^® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's disease earlier and with greater accuracy. Exagen's CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, visit or follow Exagen on LinkedIn.

Contact:

Tina Jacobsen
Exagen Inc.
...

MENAFN24022026004107003653ID1110782540

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.